US
CA
NZ
UK
AU
IND
Last update at 2025-05-22T17:04:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
Sun 20 Oct 24, 08:06 PMMichael Burry of ‘The Big Short' increases Alibaba stake, halves stock portfolio
Wed 14 Aug 24, 08:32 PMAustralian Billionaire Kerr Neilson is Selling These 15 Stocks
Fri 23 Sep 22, 01:15 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -106.48200M | -95.40200M | -35.85300M | -29.85500M | -28.97900M |
| Minority interest | - | 0.00000M | 0.00000M | -0.04700M | 0.02M |
| Net income | -105.28300M | -95.40600M | -37.24100M | -31.40200M | -28.97900M |
| Selling general administrative | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | 0.25M | 0.43M | 5.20M | 10.63M |
| Reconciled depreciation | 1.20M | 1.33M | 1.01M | 0.86M | 0.79M |
| Ebit | -108.14000M | -96.44000M | -30.09900M | -28.26800M | -28.03000M |
| Ebitda | -106.48200M | -94.75900M | -28.99200M | -27.30200M | -27.23600M |
| Depreciation and amortization | 1.66M | 1.68M | 1.11M | 0.97M | 0.79M |
| Non operating income net other | 1.66M | - | - | - | - |
| Operating income | -108.14000M | -96.44000M | -30.09900M | -28.26800M | -28.23400M |
| Other operating expenses | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Interest expense | -1.65800M | 0.00300M | 1.39M | 1.63M | 0.95M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.65M | 0.35M | 0.10M | 0.13M | 0.21M |
| Net interest income | 1.65M | 0.35M | -1.28900M | -1.50200M | -0.74000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.19900M | 0.00400M | 1.39M | 1.55M | 0.20M |
| Total revenue | 0.00000M | 0.25M | 0.43M | 5.20M | 10.63M |
| Total operating expenses | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 1.66M | 1.04M | -5.75400M | -1.58700M | -0.00500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -106.48200M | -95.40200M | -35.85300M | -29.85500M | -28.97900M |
| Net income applicable to common shares | -106.48200M | -95.40200M | -26.87700M | -28.73100M | -28.16400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 119.66M | 225.74M | 254.42M | 244.94M | 9.34M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.93M | 0.54M | 0.50M | 0.07M | 0.21M |
| Total liab | 48.99M | 45.40M | 43.60M | 34.96M | 65.35M |
| Total stockholder equity | 70.67M | 180.34M | 210.82M | 209.97M | -55.96400M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 22.90M | 17.38M | 17.25M | 10.00M | 10.45M |
| Common stock | 0.00500M | 0.00500M | 0.00400M | 0.00300M | 0.75M |
| Capital stock | 0.00500M | 0.00500M | 0.00400M | 0.00300M | 90.09M |
| Retained earnings | -416.26300M | -292.80100M | -186.31900M | -90.91700M | -148.35400M |
| Other liab | - | 19.81M | 19.81M | 2.02M | 30.21M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.15M | 0.15M | 0.15M | 0.15M |
| Cash | 111.47M | 215.51M | 244.98M | 238.60M | 3.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 28.34M | 23.13M | 19.81M | 32.26M | 26.72M |
| Current deferred revenue | - | - | - | 19.81M | 1.42M |
| Net debt | -109.01100M | -211.52600M | -239.60800M | -237.92300M | 14.42M |
| Short term debt | 1.62M | 1.52M | 1.39M | 0.68M | 9.71M |
| Short long term debt | - | - | - | - | 9.71M |
| Short long term debt total | 2.46M | 3.98M | 5.37M | 0.68M | 18.12M |
| Other stockholder equity | 486.93M | 473.13M | 397.14M | 300.89M | 2.29M |
| Property plant equipment | - | 2.73M | 6.98M | 4.10M | 4.67M |
| Total current assets | 116.41M | 220.43M | 247.29M | 240.68M | 4.51M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 180.34M | 210.82M | 209.97M | -145.30900M |
| Short term investments | - | - | - | - | - |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | 0.68M | 8.41M |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.82M | 4.23M | 1.18M | 2.46M | 5.14M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | -2.21400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00500M | 0.00400M | 0.00300M | 0.75M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -292.80100M | -186.31900M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3.25M | 5.30M | 7.13M | 4.26M | 4.83M |
| Capital lease obligations | 2.46M | 3.98M | 5.37M | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.26500M | -0.92400M | -0.59000M | -1.50900M | -0.98800M |
| Change to liabilities | 3.41M | 7.99M | -2.08900M | 22.89M | -10.18100M |
| Total cashflows from investing activities | -0.26500M | -0.92400M | -0.59000M | -1.50900M | -0.98800M |
| Net borrowings | - | - | 3.43M | 4.00M | 5.00M |
| Total cash from financing activities | 61.21M | 69.51M | 271.82M | 4.00M | 5.02M |
| Change to operating activities | -3.12400M | -0.56800M | -0.40900M | 2.21M | 0.48M |
| Net income | -106.48200M | -95.40200M | -35.85300M | -29.85500M | -28.97900M |
| Change in cash | -29.47200M | 6.37M | 234.90M | -7.15900M | -31.28600M |
| Begin period cash flow | 244.98M | 238.60M | 3.70M | 10.86M | 42.15M |
| End period cash flow | 215.51M | 244.98M | 238.60M | 3.70M | 10.86M |
| Total cash from operating activities | -90.42000M | -62.21400M | -36.33400M | -9.64500M | -35.31700M |
| Issuance of capital stock | 61.68M | 70.99M | 268.41M | 0.00000M | 0.00000M |
| Depreciation | 1.20M | 1.33M | 1.01M | 0.86M | 0.79M |
| Other cashflows from investing activities | 0.00300M | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 0.29M | 0.29M | - | - | - |
| Other cashflows from financing activities | -0.75800M | -1.48200M | 71.60M | 4.00M | 5.02M |
| Change to netincome | 14.58M | 24.43M | 1.01M | -5.81300M | 2.57M |
| Capital expenditures | 0.27M | 0.92M | 0.59M | 1.51M | 0.99M |
| Change receivables | - | 0.00300M | - | - | - |
| Cash flows other operating | -3.12400M | -0.56800M | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -29.47200M | 6.37M | - | - | - |
| Change in working capital | 0.29M | 7.42M | -2.49800M | 25.10M | -9.70400M |
| Stock based compensation | 14.56M | 25.12M | 3.02M | - | - |
| Other non cash items | 0.01M | 0.00300M | -6.47700M | -5.75200M | 2.57M |
| Free cash flow | -90.68800M | -63.13800M | -36.92400M | -11.15400M | -36.30500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BCAB Bioatla Inc |
0.02 4.53% | 0.40 | - | - | 7.12 | 3.45 | 2.07 | 0.31 |
| NVO Novo Nordisk A/S |
-0.155 0.23% | 68.05 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.95 1.40% | 68.95 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.41 1.01% | 430.91 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-10.3 1.70% | 594.32 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
11085 Torreyana Road, San Diego, CA, United States, 92121
| Name | Title | Year Born |
|---|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman | 1958 |
| Mr. Scott Andrew Smith | Pres & Director | 1962 |
| Mr. Richard A. Waldron | Chief Financial Officer | 1954 |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer | 1964 |
| Mr. Christian Vasquez | VP of Fin., Corp. Controller & Sec. | 1975 |
| Mr. Philippe Martin | Chief Clinical Devel. & Operations | 1976 |
| Lisa M. Pelton | Accounting Mang. | NA |
| Ms. Susie Melody | Sr. VP of HR | NA |
| Dr. Cathy Chang Ph.D. | Sr. VP of R&D | NA |
| Ms. Monica Sullivan | Sr. VP of Intellectual Property & Contracts | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...